GEIS 2013 guidelines for gastrointestinal sarcomas (GIST)

被引：44

作者：

Poveda, Andres ^{[1
]}

Garcia del Muro, Xavier ^{[2
]}

Antonio Lopez-Guerrero, Jose ^{[3
]}

Martinez, Virginia ^{[4
]}

Romero, Ignacio ^{[1
]}

Valverde, Claudia ^{[5
]}

Cubedo, Ricardo ^{[6
]}

Martin-Broto, Javier ^{[7
]}

机构：

[1] Inst Valenciano Oncol, Valencia 46009, Spain

[2] Avinguda Granvia Hosp, Inst Catala Oncol, Barcelona, Spain

[3] Fdn Inst Valenciano Oncol, Valencia 46009, Spain

[4] Hosp La Paz, Madrid 28046, Spain

[5] Hosp Valle De Hebron, Barcelona 08035, Spain

[6] Hosp Puerta Hierro, Madrid 28222, Spain

[7] Hosp Virgen Rocio, Seville 41013, Spain

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2014年 / 74卷 / 05期

关键词：

GIST; Imatinib; Sunitinib; CD117; c-kit; PDFGRA; STROMAL TUMORS GISTS; POSITRON-EMISSION-TOMOGRAPHY; CLINICAL-PRACTICE GUIDELINES; HIGH-DOSE IMATINIB; KINASE INHIBITOR; TYROSINE KINASE; PHASE-II; ACQUIRED-RESISTANCE; PROGNOSTIC-FACTORS; ADJUVANT IMATINIB;

D O I：

10.1007/s00280-014-2547-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Gastrointestinal stromal tumors (GIST) are the most common mesenchymal soft tissue sarcoma of the gastrointestinal tract. Correct diagnosis with thorough use of pathologic and molecular tools of GIST mutations has been of the foremost importance. GIST are usually (95 %) KIT positive and harbor frequent KIT or platelet-derived growth factor receptor alpha-activating mutations. This deep molecular understanding has allowed the correct classification into risk groups with implications regarding prognosis, essential use in the development of targeted therapies and even response prediction to this drugs. Treatment has been evolving and an update to include lessons learned from recent trials in advanced disease as well as controversies in the adjuvant setting that are changing daily practice, is reviewed here. An effort from the Spanish Group for Sarcoma Research with investigators from the group has been undertaken to launch this third version of the GIST guidelines and provide a practical means for the different disciplines that treat this complex disease.

引用

页码：883 / 898

页数：16

共 89 条

[31] Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST) [J].

Fiore, M. ;

Palassini, E. ;

Fumagalli, E. ;

Pilotti, S. ;

Tamborini, E. ;

Stacchiotti, S. ;

Pennacchioli, E. ;

Casali, P. G. ;

Gronchi, A. .

EJSO, 2009, 35 (07) :739-745

[32] Diagnosis of gastrointestinal stromal tumors: A consensus approach [J].

Fletcher, CDM ;

Berman, JJ ;

Corless, C ;

Gorstein, F ;

Lasota, J ;

Longley, BJ ;

Miettinen, M ;

O'Leary, TJ ;

Remotti, H ;

Rubin, BP ;

Shmookler, B ;

Sobin, LH ;

Weiss, SW .

HUMAN PATHOLOGY, 2002, 33 (05) :459-465

[33] SDHB immunohistochemistry: a useful tool in the diagnosis of Carney-Stratakis and Carney triad gastrointestinal stromal tumors [J].

Gaal, Jose ;

Stratakis, Constantine A. ;

Carney, J. Aidan ;

Ball, Evan R. ;

Korpershoek, Esther ;

Lodish, Maya B. ;

Levy, Isaac ;

Xekouki, Paraskevi ;

van Nederveen, Francien H. ;

den Bakker, Michael A. ;

O'Sullivan, Maureen ;

Dinjens, Winand N. M. ;

de Krijger, Ronald R. .

MODERN PATHOLOGY, 2011, 24 (01) :147-151

[34] Multiple Primary Sporadic Gastrointestinal Stromal Tumors in the Adult: An Underestimated Entity [J].

Gasparotto, Daniela ;

Rossi, Sabrina ;

Bearzi, Italo ;

Doglioni, Claudio ;

Marzotto, Alessandra ;

Hornick, Jason L. ;

Alessandra, Grizzo ;

Sartor, Chiara ;

Mandoles, Alessandra ;

Sciot, Raf ;

Debiec-Rychter, Maria ;

Dei Tos, Angelo Paolo ;

Maestro, Roberta .

CLINICAL CANCER RESEARCH, 2008, 14 (18) :5715-5721

[35]

Gastrointestinal stromal tumor meta-analysis G, 2010, J CLIN ONCOL, V1, P1247

[36] Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure [J].

George, S. ;

Blay, J. Y. ;

Casali, P. G. ;

Le Cesne, A. ;

Stephenson, P. ;

DePrimo, S. E. ;

Harmon, C. S. ;

Law, C. N. J. ;

Morgan, J. A. ;

Ray-Coquard, I. ;

Tassell, V. ;

Cohen, D. P. ;

Demetri, G. D. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (11) :1959-1968

[37] Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis [J].

Gold, Jason S. ;

Goenen, Mithat ;

Gutierrez, Antonio ;

Martin Broto, Javier ;

Garcia-del-Muro, Xavier ;

Smyrk, Thomas C. ;

Maki, Robert G. ;

Singer, Samuel ;

Brennan, Murray F. ;

Antonescu, Cristina R. ;

Donohue, John H. ;

DeMatteo, Ronald P. .

LANCET ONCOLOGY, 2009, 10 (11) :1045-1052

[38] PDGFRA activating mutations in gastrointestinal stromal tumors [J].

Heinrich, MC ;

Corless, CL ;

Duensing, A ;

McGreevey, L ;

Chen, CJ ;

Joseph, N ;

Singer, S ;

Griffith, DJ ;

Haley, A ;

Town, A ;

Demetri, GD ;

Fletcher, CDM ;

Fletcher, JA .

SCIENCE, 2003, 299 (5607) :708-710

[39] Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor [J].

Heinrich, MC ;

Corless, CL ;

Demetri, GD ;

Blanke, CD ;

von Mehren, M ;

Joensuu, H ;

McGreevey, LS ;

Chen, CJ ;

Van den Abbeele, AD ;

Druker, BJ ;

Kiese, B ;

Eisenberg, B ;

Roberts, PJ ;

Singer, S ;

Fletcher, CDM ;

Silberman, S ;

Dimitrijevic, S ;

Fletcher, JA .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) :4342-4349

[40] Molecular correlates of imatinib resistance in gastrointestinal stromal tumors [J].

Heinrich, Michael C. ;

Corless, Christopher L. ;

Blanke, Charles D. ;

Demetri, George D. ;

Joensuu, Heikki ;

Roberts, Peter J. ;

Eisenberg, Burton L. ;

von Mehren, Margaret ;

Fletcher, Christopher D. M. ;

Sandau, Katrin ;

McDougall, Karen ;

Ou, Wen-bin ;

Chen, Chang-Jie ;

Fletcher, Jonathan A. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) :4764-4774

← 1 2 3 4 5 6 7 8 9 →